论文部分内容阅读
目的:研究吸入伊洛前列素对非小细胞肺癌(NSCLC)细胞化疗敏感性的影响。方法:研究对象为2014年8月至2015年8月在我院住院治疗的40例NSCLC患者,随机分为治疗组和对照组。所有患者均予以吉西他滨联合顺铂化疗,治疗组在化疗同时予以吸入伊洛前列素。ELISA检测患者治疗前后患者血清中HIF-1α和VEGF表达水平的变化,采用Karnofsky评分评价患者功能状况,并对比两组疗效及毒副反应。结果:治疗组有效率(RR)和控制率(CDR)显著高于对照组(P<0.05);治疗组Karnofsky评分改善率优于对照组(P<0.05);治疗组毒副反应发生率低于对照组(P<0.05);治疗后两组血清中HIF-1α和VEGF的表达水平均低于治疗前,治疗组治疗后1天、21天血清中HIF-1α和VEGF的表达水平显著低于对照组同期,且治疗后21天表达水平显著低于治疗后1天(P<0.05)。结论:吸入伊洛前列素能通过调节HIF-1α和VEGF水平改善NSCLC细胞化疗敏感性,且疗效安全显著,预后好。
Objective: To study the influence of inhaling iloprost on chemosensitivity of non-small cell lung cancer (NSCLC) cells. Methods: Forty NSCLC patients hospitalized in our hospital from August 2014 to August 2015 were randomly divided into treatment group and control group. All patients were treated with gemcitabine combined with cisplatin, the treatment group in the same time be inhaled iloprost. The serum levels of HIF-1α and VEGF in patients before and after treatment were detected by ELISA. The Karnofsky score was used to evaluate the functional status of patients. The curative effect and toxicity were compared between the two groups. Results: The effective rate (RR) and control rate (CDR) in the treatment group were significantly higher than those in the control group (P <0.05). The improvement rate of Karnofsky score in the treatment group was better than that in the control group (P <0.05) (P <0.05). The levels of HIF-1α and VEGF in serum of the two groups were lower than those before treatment, and the levels of HIF-1α and VEGF in serum of the two groups were significantly lower At the same period of the control group, the expression level at 21 days after treatment was significantly lower than that at 1 day after treatment (P <0.05). Conclusion: Inhaled iloprost can improve the chemosensitivity of NSCLC cells by regulating the levels of HIF-1α and VEGF, and the therapy is safe and the prognosis is good.